Total Payments
$698.28
2024 Payments
$64.25
Companies
10
Transactions
19
Medicare Patients
3,925
Medicare Billing
$330,714
Payment Breakdown by Category
Food & Beverage$693.28 (99.3%)
Education$5.00 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $693.28 | 18 | 99.3% |
| Education | $5.00 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $279.45 | 4 | $0 (2021) |
| Novo Nordisk Inc | $197.11 | 7 | $0 (2024) |
| GlaxoSmithKline, LLC. | $72.48 | 1 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $47.34 | 1 | $0 (2022) |
| Esperion Therapeutics, Inc. | $23.77 | 1 | $0 (2020) |
| AbbVie, Inc. | $20.19 | 1 | $0 (2019) |
| Dexcom, Inc. | $17.55 | 1 | $0 (2024) |
| Medtronic MiniMed, Inc. | $16.51 | 1 | $0 (2020) |
| Amgen Inc. | $12.18 | 1 | $0 (2020) |
| PFIZER INC. | $11.70 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $64.25 | 3 | Novo Nordisk Inc ($46.70) |
| 2023 | $86.10 | 2 | GlaxoSmithKline, LLC. ($72.48) |
| 2022 | $60.84 | 2 | Bayer HealthCare Pharmaceuticals Inc. ($47.34) |
| 2021 | $243.79 | 3 | AstraZeneca Pharmaceuticals LP ($149.67) |
| 2020 | $93.33 | 6 | Novo Nordisk Inc ($29.17) |
| 2019 | $20.19 | 1 | AbbVie, Inc. ($20.19) |
| 2017 | $129.78 | 2 | AstraZeneca Pharmaceuticals LP ($129.78) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $27.30 | General |
| Category: Obesity | ||||||
| 07/26/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: Endocrinology | ||||||
| 05/13/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Diabetes | ||||||
| 09/13/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $72.48 | General |
| Category: RESPIRATORY | ||||||
| 06/22/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Obesity | ||||||
| 05/04/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $47.34 | General |
| Category: Cardio-renal | ||||||
| 02/14/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Diabetes | ||||||
| 11/04/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $94.12 | General |
| Category: Diabetes | ||||||
| 03/25/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Respiratory | ||||||
| 03/08/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Respiratory | ||||||
| 12/02/2020 | Medtronic MiniMed, Inc. | Guardian Connect (Device) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: Continuous Glucose Monitoring | ||||||
| 11/24/2020 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 04/02/2020 | Amgen Inc. | Aimovig (Biological), Otezla, Repatha | Food and Beverage | In-kind items and services | $12.18 | General |
| Category: Neuroscience | ||||||
| 03/05/2020 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $11.70 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/10/2020 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Diabetes | ||||||
| 01/16/2020 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: Diabetes | ||||||
| 04/18/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Immunology | ||||||
| 11/09/2017 | AstraZeneca Pharmaceuticals LP | BYDUREON (Drug) | Food and Beverage | In-kind items and services | $124.78 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/03/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Education | In-kind items and services | $5.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 579 | 1,005 | $110,855 | $54,793 |
| 2022 | 15 | 924 | 1,532 | $156,648 | $78,818 |
| 2021 | 17 | 1,180 | 2,128 | $199,575 | $102,126 |
| 2020 | 17 | 1,242 | 1,972 | $204,424 | $94,978 |
Total Patients
3,925
Total Services
6,637
Medicare Billing
$330,714
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 114 | 295 | $52,189 | $23,529 | 45.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 97 | 275 | $32,708 | $15,993 | 48.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 44 | 44 | $8,111 | $5,340 | 65.8% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 44 | 44 | $3,960 | $3,452 | 87.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $4,007 | $1,398 | 34.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 96 | 163 | $4,075 | $1,353 | 33.2% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 24 | 24 | $960.00 | $803.76 | 83.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 24 | 24 | $960.00 | $700.08 | 72.9% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 36 | 36 | $1,089 | $622.64 | 57.2% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 33 | 33 | $1,009 | $570.97 | 56.6% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 20 | 20 | $841.54 | $484.80 | 57.6% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 19 | 19 | $817.00 | $466.45 | 57.1% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2023 | 13 | 13 | $130.00 | $79.43 | 61.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 139 | 439 | $77,117 | $35,085 | 45.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 124 | 305 | $36,789 | $18,431 | 50.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 72 | 72 | $13,375 | $9,045 | 67.6% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 75 | 75 | $6,750 | $6,044 | 89.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 21 | 21 | $5,775 | $2,290 | 39.7% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 57 | 57 | $2,280 | $1,771 | 77.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 57 | 57 | $2,280 | $1,570 | 68.9% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2022 | 73 | 73 | $2,236 | $1,302 | 58.2% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 62 | 62 | $1,895 | $1,084 | 57.2% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2022 | 31 | 31 | $1,296 | $796.00 | 61.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 113 | 211 | $5,275 | $625.23 | 11.9% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2022 | 13 | 13 | $559.00 | $333.58 | 59.7% |
About Dr. Mac Montilus, MD
Dr. Mac Montilus, MD is a Multi-Specialty healthcare provider based in Lumberton, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922044791.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mac Montilus, MD has received a total of $698.28 in payments from pharmaceutical and medical device companies, with $64.25 received in 2024. These payments were reported across 19 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($693.28).
As a Medicare-enrolled provider, Montilus has provided services to 3,925 Medicare beneficiaries, totaling 6,637 services with total Medicare billing of $330,714. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Multi-Specialty
- Other Specialties Community/Behavioral Health, Internal Medicine
- Location Lumberton, NC
- Active Since 06/21/2006
- Last Updated 10/17/2025
- Taxonomy Code 261QM1300X
- Entity Type Individual
- NPI Number 1922044791
Products in Payments
- BREZTRI (Drug) $149.67
- BYDUREON (Drug) $124.78
- RYBELSUS (Drug) $110.13
- AREXVY (Drug) $72.48
- Kerendia (Drug) $47.34
- Ozempic (Drug) $46.06
- Wegovy (Drug) $40.92
- NEXLETOL (Drug) $23.77
- Humira (Biological) $20.19
- Dexcom G6 Transmitter (Medical Supply) $17.55
- Guardian Connect (Device) $16.51
- Aimovig (Biological) $12.18
- ELIQUIS (Drug) $11.70
- FARXIGA (Drug) $5.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.